Un­de­terred by a pan­dem­ic, Gilde Health­care rais­es their largest fund yet

When Pieter van der Meer start­ed rais­ing the cap­i­tal for Gilde Health­care’s fifth fund in the wan­ing months of 2019, he had his eyes on a dif­fer­ent chain of events that could change the health­care sys­tem and per­haps even play to his firm’s ad­van­tage: The US pres­i­den­tial elec­tion.

Since rais­ing their third fund in 2011, the 34-year-old Dutch firm had fo­cused on val­ue-based care. They chose late-stage biotechs that came up with new de­vices and de­liv­ery sys­tems for de-risked es­tab­lished com­pounds, and when they chose pre­clin­i­cal biotechs, they spoke with po­ten­tial phar­ma part­ners, pay­ers and reg­u­la­tors to ask where and at what prices the drug made sense. As the De­mo­c­ra­t­ic pri­ma­ry be­came a con­test over how to low­er health­care costs, it looked like a strat­e­gy that could pay off.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.